Growth Metrics

Iridex (IRIX) Long-Term Debt Repayments (2011 - 2025)

Iridex's quarterly Long-Term Debt Repayments came in at $4.0 million in Q1 2025, up 1716.97% quarter-over-quarter from $218000.0 in Q4 2024.

Iridex has reported Long-Term Debt Repayments for 3 years, with the latest figure at $4.0 million in Q1 2025.

  • For the quarter ending Q1 2025, Long-Term Debt Repayments changed N/A year-over-year to $4.0 million; the trailing twelve-month figure through Jan 2026 stood at $4.0 million (up 1716.97% YoY), and the FY2026 full-year result was $4.0 million, up 1716.97% from the prior year.
  • Long-Term Debt Repayments for Q1 2025 stood at $4.0 million, up from $218000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $4.0 million in Q1 2025, with the low at $218000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Iridex 18.87 Mn 14.27 Mn 4.74 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2025 3.96 Mn
Mar 29, 2025 3.96 Mn
Dec 28, 2024 218,000.00
Dec 28, 2024 218,000.00
Dec 31, 2011 -9.40 Mn
Dec 31, 2011 -9.40 Mn